Chang‐Gong Liu
Papers
1
Total Citations
22
H-Index
1
About
Chang-Gong Liu is a leading translational researcher whose work centers on inflammatory breast cancer (IBC)—the most lethal form of breast cancer, with a five-year survival rate of just 62–68%. Recognizing the urgent need for better preclinical models, Dr. Liu developed a clinically relevant patient-derived xenograft (PDX) ex vivo platform that faithfully recapitulates IBC biology. This breakthrough model, described in a 2018 study with 22 citations, enables the evaluation of tumor-specific therapies in a way that standard cell lines cannot, bridging a critical gap between laboratory discovery and clinical application. By creating a tool that preserves the aggressive, metastatic features of IBC, Dr. Liu has empowered researchers to test novel treatments more accurately and accelerate the development of targeted interventions for this devastating disease. Their work not only advances our understanding of IBC’s unique pathophysiology but also provides a practical, high-fidelity system for drug screening—offering new hope for patients facing the poorest prognosis among breast cancer subtypes.
Research Focus
Key Achievements
Top Papers
- 1